Veronica Mullally Muñoz


  New York, USA
 +1 646-878-0881
 This email address is being protected from spambots. You need JavaScript enabled to view it.
 Download vCard

Current Time
01:43 PM

Veronica Muñoz is a partner in Pearl Cohen’s New York office. She is a trial lawyer and concentrates her practice on patent litigation in the life sciences. She has extensive experience in both bench and jury trials and in the appellate process. She has over 18 years experience representing both Fortune 500 companies and small companies handling disputes involving a wide range of technologies including: pharmaceuticals, biologics, siRNA, gene sequencing, transgenic plants, cardiovascular stents, medical devices and mechanical and electrical products. She has extensive experience in Hatch-Waxman litigation including achieving a favorable settlement of a 505(b)(2) case on the eve of trial; summary judgment of non-infringement in two successive ANDA cases and successfully defending a trial court's decision in the Court of Appeals for the Federal Circuit and on petition for certiorari. Other representative matters include: obtaining a preliminary injunction in a trade secret case involving siRNA; winning a priority of invention dispute at a bench trial in a Section 146 action involving a commercially valuable gene; winning a jury trial involving patented transgenic plant technology; forcing a withdrawal of suit and favorable settlements in infringement actions involving transgenic crops: litigating a biotechnology case in the ITC: four jury trials involving infringement of cardiovascular stent patents; a three month long arbitration involving licensing of a erythropoietin-type biologic; successfully resolving an infringement case involving dental implant technology; and successful enforcement of a patent on photographic equipment.

Before attending law school, Veronica was a biochemist and worked in both academic research and in industry. She did post-graduate research on the gut hormone secretin and later worked on a leukemia research team at the John Radcliffe hospital in Oxford, UK, studying purine and pyrimidine metabolism. She went on to become a research scientist at Celltech, Ltd., UK, where she helped develop some of the first diagnostic uses of monoclonal antibodies.